<DOC>
	<DOC>NCT01369225</DOC>
	<brief_summary>This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.</brief_summary>
	<brief_title>Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Successful completion of study B2601001 MMSE 12 or greater Study B2601001 Week 32 MRI with clinically important exclusionary findings. Experienced SAE, vasogenic edema and/or intracranial hemorrhage in study B2601001</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Safety Study</keyword>
	<keyword>Open Label</keyword>
</DOC>